Wix.com Ltd. (WIX) Spending and interest coverage
- R&D / revenue · 12 months: Value 32.39%; Formula and calculation Research and development expense / revenue. Period ending 2025-12-31..
- Stock-based compensation / revenue · 12 months: Value 11.91%; Formula and calculation Share-based compensation / revenue. Period ending 2025-12-31..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2025-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 32.39% | Research and development expense / revenue. Period ending 2025-12-31. $645.50M ÷ $1.99B × 100 ≈ 32.39% |
| Stock-based compensation / revenue · 12 months | 11.91% | Share-based compensation / revenue. Period ending 2025-12-31. $237.38M ÷ $1.99B × 100 ≈ 11.91% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 645.50M USD | Research and Development Expense |
| Revenue | 1.99B USD | |
| Stock-based compensation | 237.38M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 1.75M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $645.50M | $1.99B | $237.38M | $1.75M | (m) | 32.39% | 11.91% | (m) | (m) |
| 2024-12-31 | $495.28M | $1.76B | $240.72M | $100.14M | (m) | 28.13% | 13.67% | (m) | (m) |
| 2023-12-31 | $481.29M | $1.56B | $224.63M | $-24.38M | (m) | 30.82% | 14.38% | (m) | (m) |
| 2022-12-31 | $482.86M | $1.39B | $236.84M | $-285.35M | (m) | 34.80% | 17.07% | (m) | (m) |
| 2021-12-31 | $424.94M | $1.27B | $221.39M | $-325.53M | (m) | 33.47% | 17.44% | (m) | (m) |
| 2020-12-31 | $320.28M | $988.76M | $147.31M | $-197.34M | (m) | 32.39% | 14.90% | (m) | (m) |
| 2019-12-31 | $250.79M | $761.09M | $109.34M | $-80.25M | (m) | 32.95% | 14.37% | (m) | (m) |
| 2018-12-31 | $198.91M | $603.70M | $72.33M | $-30.63M | (m) | 32.95% | 11.98% | (m) | (m) |
| 2017-12-31 | $153.63M | $425.64M | $47.70M | $-50.01M | (m) | 36.10% | 11.21% | (m) | (m) |
| 2016-12-31 | $105.37M | $290.10M | $28.05M | $-44.03M | (m) | 36.32% | 9.67% | (m) | (m) |
| 2015-12-31 | $77.65M | $203.52M | $18.75M | $-48.63M | (m) | 38.15% | 9.21% | (m) | (m) |
| 2014-12-31 | $57.83M | $141.84M | $13.94M | $-55.64M | (m) | 40.77% | 9.83% | (m) | (m) |
| 2013-12-31 | $29.66M | $80.47M | $7.05M | $-26.53M | $262.00K | 36.86% | 8.77% | -101.25× | Reported |
| 2012-12-31 | $16.78M | $43.68M | $1.02M | $-14.96M | (m) | 38.42% | 2.34% | (m) | (m) |
| 2011-12-31 | $14.75M | $24.60M | $4.73M | $-22.36M | (m) | 59.94% | 19.24% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.